Schedule 13G ownership disclosure

Mineralys Therapeutics Inc

Common Stock · CUSIP: 603170101

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Adams Street Partners, LLC

    Shares: 1,129,807.00 · Class: 2.3%

  • Adams Street 2016 Direct Venture/Growth Fund LP

    Shares: 91,126.00 · Class: 0.2%

  • Adams Street 2017 Direct Venture/Growth Fund LP

    Shares: 117,878.00 · Class: 0.2%

  • Adams Street 2018 Direct Venture/Growth Fund LP

    Shares: 176,038.00 · Class: 0.4%

  • Adams Street 2019 Direct Growth Equity Fund LP

    Shares: 98,889.00 · Class: 0.2%

  • Adams Street 2020 Direct Growth Equity Fund LP

    Shares: 105,448.00 · Class: 0.2%

  • Adams Street 2021 Direct Growth Equity Fund LP

    Shares: 102,305.00 · Class: 0.2%

  • Adams Street Growth Equity Fund VII LP

    Shares: 438,123.00 · Class: 0.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-013268
Form type
SCHEDULE 13G/A
Filer
ADAMS STREET PARTNERS LLC
CIK
CIK 1193586
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub